[1] Jiang S, Wu H, Fu R, et al. The outcome of primary hepatic carcinoid tumor: a retrospective study based on propensity score matched survival analysis. Front Oncol, 2021, 11: 609397.
[2] Yang K, Cheng Y S, Yang J J, et al. Primary hepatic neuroendocrine tumor with multiple liver metastases: A case report with review of the literature. World J Gastroenterol, 2015, 21(10): 3132-3138.
[3] Han Y, Li L, Sun H. Computed tomography and magnetic resonance imaging in the diagnosis of primary neuroendocrine tumors of the liver. World Neurosurg, 2020, 138: 723-731.
[4] Chen Z, Xiao HE, Ramchandra P, et al. Imaging and pathological features of primary hepatic neuroendocrine carcinoma: An analysis of nine cases and review of the literature. Oncol Lett, 2014, 7(4): 956-962.
[5] Kim JM, Lee WA, Shin HD, et al. Cystic primary hepatic neuroendocrine tumor. Korean J Gastroenterol, 2021, 78(5): 300-304.
[6] Xia Y, Zhang L, Wu H, et al. Primary hepatic neuroendocrine tumor with multiple liver metastases: A case report with literature review. J Int Med Res, 2020, 48(6): 300060520932114.
[7] Uri I, Grozinsky-Glasberg S. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol, 2018, 4: 16.
[8] Deluzio MR, Barbieri AL, Israel G, et al. Two cases of primary hepatic neuroendocrine tumors and a review of the current literature. Ann Hepatol, 2017, 16(4): 621-629.
[9] Jung J, Hwang S, Hong SM, et al. Long-term postresection prognosis of primary neuroendocrine tumors of the liver. Ann Surg Treat Res, 2019, 97(4): 176-183.
[10] Nakatake R, Ishizaki M, Matui K, et al. Combination therapies for primary hepatic neuroendocrine carcinoma: a case report. Surg Case Rep, 2017, 3(1): 102.
[11] Chan DL, Segelov E, Singh S. Everolimus in the management of metastatic neuroendocrine tumours. Therap Adv Gastroenterol, 2017, 10(1): 132-141.
[12] Mikolajczak R, Maecke HR. Radiopharmaceuticals for somatostatin receptor imaging. Nucl Med Rev Cent East Eur, 2016, 19(2): 126-132.
[13] Jiao X, Luan W, Peng X, et al. Effects of tumor origins and therapeutic options on the prognosis of hepatic neuroendocrine tumors: A retrospective study. Medicine (Baltimore), 2020, 99(51): e23655.
[14] Li YF, Zhang QQ, Wang WL. Clinicopathological characteristics and survival outcomes of primary hepatic neuroendocrine tumor: a surveillance, epidemiology, and end results (SEER) population-based study. Med Sci Monit, 2020, 26: e923375. |
